Compare Boston Beer Company Inc (SAM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs TransMedics Group Inc — how do they compare? Boston Beer Company Inc trades at $170.51 (market cap $1.76B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (949,331 versus 264,496). Which is the better fit depends on your goals — on Pluang, investors hold Boston Beer Company Inc for 59 Days and TransMedics Group Inc for 24 Days on average.
| SAM | TMDX | |
|---|---|---|
Market Cap | $1.76B | $2.74B |
Volume | 264,496 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $150.42 |
52-Week Low | $161.08 | $61.99 |
Typical Hold Time | 59 Days | 24 Days |
Enterprise Value | $1.53B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $170.51, up 1.4% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold (71.87%) with a $204.44 price target.
SAM faces headwinds from declining alcohol consumption and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near support at $169 with upside to analyst targets, though execution risks and margin pressure require monitoring. Current valuation appears reasonable relative to historical levels.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
